Shares of Aurobindo Pharma fell by 7% to ₹1,098.10 after the company disclosed that the U.S. Food and Drug Administration (US FDA) had issued five observations for its step-down subsidiary Eugia Steriles’ facility in Andhra Pradesh. These observations were made following a pre-approval inspection (PAI) of the facility located in Parawada Mandal, Anakapalli District, from February 10-18, 2025.
The company clarified that the observations are procedural in nature, and it intends to respond to them within the required timeframe. Eugia Steriles is a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of Aurobindo Pharma.
As per stock details, Aurobindo Pharma’s shares closed at ₹1,098.10, reflecting a 5.61% decline or ₹65.25 from the previous close of ₹1,163.35. The stock had a day range of ₹1,115.00 to ₹1,115.00, and it is trading within a year range of ₹984.30 to ₹1,592.00. The market capitalization stands at ₹647.59 billion, with an average volume of 918.27K.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Always conduct your own research or consult a financial advisor before making investment decisions.
